Table 4.
Recurrence-free survival analysis of 125 bladder cancer patients
| polymorphisms | genotype | N (all, n = 125) | N (reoccurence, n = 71) | HR (95% CI) |
|---|---|---|---|---|
| rs10127190 | TT | 125 (100.0%) | 71 (56.8%) | 1 |
| TA | 0 | 0 | - | |
| AA | 0 | 0 | - | |
| rs11536887 | AA | 125 (100.0%) | 71 (56.8%) | 1 |
| AG | 0 | 0 | - | |
| GG | 0 | 0 | - | |
| rs3734657 | CC | 117 (93.6%) | 66 (56.4%) | 1 |
| CT | 8 (6.4%) | 5 (62.5%) | 1.244 (0.501, 3.090) | |
| TT | 0 | 0 | - | |
| rs41314515 | CC | 125 (100.0%) | 71 (56.8%) | 1 |
| TC | 0 | 0 | - | |
| TT | 0 | 0 | - | |
| rs5743786 | TT | 125 (100.0%) | 71 (56.8%) | 1 |
| TC | 0 | 0 | - | |
| CC | 0 | 0 | - | |
| rs72552316 | TT | 125 (100.0%) | 71 (56.8%) | 1 |
| TC | 0 | 0 | - | |
| CC | 0 | 0 | - | |
| rs5743823 | TT | 123 (98.4%) | 70 (56.9) | 1 |
| TC | 2 (1.6%) | 1 (50.0%) | 0.946 (0.131, 6.816) | |
| CC | 0 | 0 | - | |
| rs7869402 | CC | 103 (82.4%) | 56 (54.4%) | 1 |
| CT | 19 (15.2%) | 13 (68.4%) | 1.278 (0.698, 2.339) | |
| TT | 3 (2.4%) | 2 (66.7%) | 1.041 (0.514, 2.107) |